From Lab to Launch by Qualio

Ever wondered about your genes and overall health?  In today's episode, we will talk about just that. with Dr. J Dunn. We go over wholistic kinesiology and wholistic methylation. For over 30 years, she has practiced natural medicine, researched, and taught her groundbreaking techniques to hundreds of individuals who, like her, are on a quest to find an alternative solution to allopathic medicine.

Dr. Dunn began her career in the Natural Health Industry after a long bout of ill health, which drove her to seek out alternative healing methods.  The results she experienced piqued her interest in Kinesiology, and she decided to study and learn this amazing technique herself.  She eventually developed her own technique, combining anatomy, physiology, emotional work, bodywork, and nutrition to create Wholistic Kinesiology. 

Her philosophy is to treat the person as a whole being, not just a collection of parts and symptoms.

Show notes: 

https://www.youtube.com/channel/UCI4Ocuu6muj1pM0Z8iv-4TA

https://wholisticmethylation.com/

https://myhappygenes.com/

https://www.facebook.com/MyHappyGenes/ 

Qualio website:
https://www.qualio.com/

Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez

Qualio website:
https://www.qualio.com/

Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez

Are you a life sciences start-up founder and want to bring your business to market, but don't know how? Marketing is something that is ever-evolving but should be part of every business' strategy.  In today's episode, you will dive into marketing strategies, testing, industry regulations, and more in the healthcare sector with Jason and Scott from Webtek Interactive. Webtek Interactive is a full-service marketing agency that works with enterprise clients. They specialize in digital strategy for companies in the Healthcare and wellness space.

About Justin
Justin’s background is in marketing online businesses and technical sciences. He’s consulted with over 300 businesses worldwide and worked in-house for companies like CHG Healthcare Services and Skullcandy.

About Scott
Scott is an entrepreneurial Kiwi with 20 years of experience in organic search marketing. Beyond partnering with healthcare companies, Scott’s interest in the life sciences extends into biohacking and life extension.

About Webtek
Successful marketing in today’s ever-changing, online landscape requires multidisciplinary skill,  proven strategy, and perfectly executed development. Luckily, we’ve got the team and the tools for the job. (In fact, this is kind of our whole deal.) 

We’re a full-service digital marketing agency with offices in Salt Lake City, UT, and Austin, TX. Your goals are our goals, and with our decades of expertise, we’ll help you meet them. We handle the complicated stuff—all you have to focus on is minding your business (we’ll mind it,  too).

 Links

Webtek Interactive: https://webtek.co/

Justin Crawmer | LinkedIn: https://www.linkedin.com/in/justincrawmer/

Scott Miscall | LinkedIn: https://www.linkedin.com/in/scottmiscall/

Qualio website:
https://www.qualio.com/

Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez

Qualio website:
https://www.qualio.com/

Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez

We all experienced the importance of at-home testing from the Covid19 pandemic and today's guest is helping bring rapid, affordable, and accurate tests to everyone including traditionally underserved areas. 

Dive into how Domus Diagnostics got started, the importance of Nucleic Acid Testing, and getting started with clinical trials to get FDA clearance with Kelly and Paul on this episode of From Lab to Launch.

About Paul Chapman
From sales representative to CEO, Board Member and Angel Investor, Paul Chapman has over 25 years of international business leadership experience in Molecular Diagnostics, Point of Care Diagnostics, Medical Devices and Life Sciences. He is skilled at change agent and is a creative, action-oriented leader with a broad base of international Diagnostic, Medical Device and Life Sciences executive experience.  Whether creating a new business or optimizing existing business models, Paul has created significant value by focusing on development of a high-performance culture through professional "A+" teams that he helps build.

About Domus Diagnostics
Domus Diagnostics  seeks to create tests for infectious diseases that are affordable, user-friendly, accurate, and rapid enough to address the needs raised by current and future public health crises. All this not only in the US but in every global market including underserved areas - talk about a big vision!

Links
Domus Diagnostics:
https://www.domusdx.com/

Paul’s LinkedIn:
 https://www.linkedin.com/in/paul-chapman-7b44508/

Qualio website:
https://www.qualio.com/

Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez 

Qualio website:
https://www.qualio.com/

Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez

Today on the show we're joined by Shuo Qiao, Co-founder and Chief Technology Officer of Moving Analytics. We discuss his career path and how it earned him a spot on the Forbes 30 Under 30 list, his interest in computer science, and crossing paths with his future business partner. Dive into funding strategies, the rise and global impact of telehealth, and the future of digital health tech on this episode of From Lab to Launch.

About Shuo Qiao
Shuo Qiao is the Co-founder and Chief Technology Officer of Moving Analytics. Shuo earned his bachelor's degree in computer science degree from Beijing Jiaotong University and the top engineering university in India, the Indian Institute of Technology Madras. In 2013, he moved to the US to pursue his master's degree in computer science from the University of Southern California. He’s now the Co-founder and Chief Technology Officer of Moving Analytics, a digital health company that reduces the chance of a heart attack through digital cardiovascular disease prevention programs.

About Moving Analytics
Moving Analytics is a digital health company with the mission to conquer cardiovascular disease as the leading cause of death by empowering people with tools to adopt healthy lifestyles. They work with a multidisciplinary team of cardiologists, nurses, nutritionists, and exercise physiologists to create personalized rehab programs for heart attack patients which they can access anywhere through their mobile phones.

Links
Shuo Qiao | LinkedIn:
https://www.linkedin.com/in/shuo-qiao-0b813452/

Moving Analytics:
https://www.movinganalytics.com/

Forbes 30 Under 30:
https://www.forbes.com/30-under-30/2018/healthcare/

Qualio website:
https://www.qualio.com/

Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez 

Qualio website:
https://www.qualio.com/

Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez

Can a chemical found in citrus fruit curb cancer and save lives through early detection? Today on the show, we'll talk about the possibilities with Dr. David Suhy, Cofounder and Chief Medical Officer of Earli. Earli was founded with the mission to make cancer a benign experience by catching and curing it early.

According the the American Cancer Society, 40% of people will be diagnosed with cancer at some point in their lifetime. And a third will die from it. What if there was a way to detect and confirm the presence of cancer by inducing synthetic biomarkers? You could catch cancer when it's most treatable and save countless lives. Learn more about this exciting technology and get inspired by David's insights.

About David Suhy
Dr. David Suhy is the Chief Scientific Officer and Cofounder of Earli. He is a gene therapy expert, experienced in bio ventures both private and public. He has led gene therapy ideas from inception through Phase 2 clinical trials, and is recognized as a leader that science teams love to work with.

Before Earli, he was the CSO at Benitec Biopharma where he oversaw development paths for products in or near term clinical studies, including Hepatitis C Virus (HCV), Head and Neck Squamous Cell Carcinoma (HNSCC), and Oculopharyngeal Muscular Dystrophy (OPMD). He developed the first non-withdrawable, systemic RNAi compound used clinically in human subjects. He previously held scientific leadership roles at Tacere Therapeutics, Takara Bio, Anatara and PPD.  He earned his PhD in Biochemistry, Molecular Biology and Cell Biology  from Northwestern University and completed his post doctoral training at Stanford University.

He's a father to three teenagers, and he loves making pizza in his large wood-fired oven in his backyard. David is married to a neuroscientist, Dr. Joyce Suhy, who knows the risks of science, and is convinced that with David’s passion, Earli will accomplish its purpose.

About Earli
Earli was founded in June of 2018 by Dr. Sam Gambhir, Cyriac Roeding and Dr. David Suhy. Earli is developing  a technique, originally from Stanford University, to trigger the production of synthetic biomarkers as a means to detect, target and destroy cancer cells. Earli is currently enrolling for their clinical trial in Australia. 

Links
David Suhy | LinkedIn:
https://www.linkedin.com/in/davidsuhy

Earli:
https://www.earli.com

Earli Clinical Trial News:
https://bit.ly/3A3bQ53

Sam Gambhir | Wikipedia:
https://en.wikipedia.org/wiki/Sanjiv_Sam_Gambhir

Qualio website:
https://www.qualio.com/

Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez 

Qualio website:
https://www.qualio.com/

Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez

Today we’re catching up with Dr. Heather Underwood, CEO of EvoEndo. EvoEndo recently completed an $8.4 million Series A financing round on the heels of 510(k) FDA clearance in early 2022. We first spoke with Dr. Underwood in June of 2021. In this episode, we chart a course through her accomplishments, lessons learned through the FDA clearance process, working with CROs, and hear firsthand about the challenges she’s tackled as Chief Executive of a medical device startup ready to revolutionize clinical endoscopy practice with a safer, faster, cost-effective alternative. 

About EvoEndo
EvoEndo, founded in 2017 by Dr. Joel Friedlander (Chief Medical Officer), is making unsedated transnasal endoscopy a reality. General anesthesia has been the standard of care for pediatric patients undergoing endoscopies. This can be a traumatic experience, especially for patients with chronic health conditions who may require the procedure several times a year. But EvoEndo’s single-use small-diameter device for unsedated transnasal endoscopy is ready to transform this medical necessity. The company received 510(K) clearance from the FDA in February of 2022 and is poised for a commercial launch of its innovative product. 

About Dr. Heather Underwood
Dr. Heather Underwood joined EvoEndo as CEO in 2019 after completing the Stanford Biodesign Innovation Fellowship for medical devices. 

Dr. Underwood completed her Ph.D. at the University of Colorado Boulder's ATLAS program where she developed and implemented clinical decision support systems for midwives and nurses in Kenya, receiving the NSF Graduate Research Fellowship grant and a Gates Grand Challenges grant to support her research. She has spent the last 10 years founding and leading medical device startups, non-profit life science organizations, and innovative academic initiatives. 

Links
Heather Underwood | LinkedIn:
https://www.linkedin.com/in/hmunderwood/

EvoEndo:
https://evoendo.com/

Titan100:
https://www.titan100.biz/2022coloradotitan100

Proxima CRO:
https://www.proximacro.com/

Qualio website:
https://www.qualio.com/

Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez 

Qualio website:
https://www.qualio.com/

Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez

Today we speak with developer turned health-tech founder Gulé Sheikh. We discuss her innovations and entrepreneurship at a leading tele-health company, her experience in technology, and the importance of representation. 

In the early 20th century, women led computer programming and made huge contributions to the field. From Ada Lovelace’s algorithm and Grace Hopper’s pioneering work on COBOL to World War II codebreaking at Bletchley Park and Katherine Johnson’s calculations critical to NASA spaceflights. Yet, when Gulé started her career 23 years ago, she was one of only 5 women in a class of 300 Computer Programming graduates. Gulé went on to found a successful health-tech company which she scaled 1000% and sold in 2019 after 7 years of running it. Join us as Gulé reflects on her experience in the tech industry.

About Gulé Sheikh
Gulé Sheikh is a technologist by trade and former executive that founded the health-tech company eazyScripts, a top telemedicine software provider focused on the virtual care space. She developed the only proprietary algorithm for price transparency at the point of care in the US.  She was interviewed by Melinda Gates as one of the few health-tech startup owners that raised over $2MM in the Midwest. Gulé is a passionate technologist with 22+ years in IT, and is now the Senior Strategic Success Manager in Healthcare at Salesforce.

Links
Gulé Sheikh | LinkedIn:
https://www.linkedin.com/in/gulesheikh/

Gulé Sheikh | Twitter:
https://twitter.com/gulesheikh

eazyScripts:
https://www.eazyscripts.com/

Women in Computing | Wikipedia:
https://en.wikipedia.org/wiki/Women_in_computing

Qualio website:
https://www.qualio.com/

Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez 

Qualio website:
https://www.qualio.com/

Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez

Non-invasive ventilation (NIV) is a life-saving tool used throughout ICUs to manage respiratory failure. The traditional form of non-invasive ventilation, a tight-fitting mask placed over a patient's nose and mouth, comes with significant drawbacks. What if there was an option to treat patients with respiratory failure that improved outcomes while reducing the likelihood for invasive intubation? 

Today on the show, we speak with Aurika Savickaite about an FDA-approved alternative—helmet-based ventilation—that improves patient outcomes with its future forward design, has already been used in Italian hospitals for over 20 years, and played a significant roll in saving the lives of COVID patients.

About Aurika Savickaite and HelmetBasedVentilation.com
Aurika Savickaite is the founder of HelmetBasedVentilation.com, a Registered Nurse, Vision Circle member at Space for Humanity, and holds an MSN from Rush University College of Nursing. Aurika studied the benefits of helmet-based ventilation and played an integral role in a three-year trial at the University of Chicago that successfully tested the helmet ventilator. Her Master's capstone project at Rush focused on non-invasive positive pressure ventilation based on her experience with the helmet. She is a passionate advocate for improving patient outcomes and founded HelmetBasedVentilation.com, a MedTech startup with the aim of training healthcare professionals on this technology, sharing knowledge, and contributing to the fight against COVID.

Links:
HelmetBasedVentilation:
https://www.helmetbasedventilation.com/

Comparison infographic:
https://www.helmetbasedventilation.com/post/infographic-comparison-bubble-helmet-hood-niv-face-mask-invasive-mechanical-ventilation

Aurika Savickaite | LinkedIn:
https://www.linkedin.com/in/aurikasavickaite/

U of Chicago | Helmet-based Ventilation News: https://www.uchicagomedicine.org/forefront/patient-care-articles/helmet-based-ventilation-is-superior-to-face-mask-for-patients-with-respiratory-distress

Qualio website:
https://www.qualio.com/

Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez 

Qualio website:
https://www.qualio.com/

Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez

The average cost of developing a new drug is estimated at over $2 billion. Roughly 10% of pre-clinical drugs ever make it to human trials. And each year, $50 billion is “misspent” in the trial & error method of research and development. An AI-enabled “decision engine” could help researchers find cures to rare diseases, bridge the translational gap between animal models to human systems, and move faster in drug development reducing associated R&D costs. 

Today on the show we chat with Jo Varshney, the founder of VeriSIM Life, about the AI-enabled technology that is cutting the time for drug development in half. Searching for a drug candidate for bone cancer led Dr. Varshney to tackle the challenges of better predicting outcomes, improving methods for drug discovery, and building models closer to human systems.

About Jo Varshney and VeriSIM Life
Dr. Jo Varshney is a multi-disciplinary and celebrated leader in veterinary & human health development. She is the founder and CEO of VeriSIM Life, which is building AI-enabled biosimulation technology to empower researchers to predict how potential drug candidates will interact in animal models. Dr. Varshney holds a Ph.D. in Comparative Oncology and Genomics from the University of Minnesota, a Master's Degree in Translational Pathobiology & Bioinformatics from Penn State University, and a Doctorate of Veterinary Medicine from the College of Veterinary Science & Animal Husbandry. She serves as a Scientific Advisor at SVAI, a San Francisco-based non-profit organization promoting education and cooperative research at the intersection of computational and life sciences.

Links: 

VeriSIM Life

LinkedIn | Jo Varshney

Genomics Hackathon

Wikipedia | Drug Discovery

Wikipedia | The Translational Gap

Qualio Website

Previous episodes: https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show: https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez

Qualio website:
https://www.qualio.com/

Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez

What if you started a company like Roche (est. in 1896) from the ground up? How would you approach drug development differently given enabling technology available today? That's the question Diego Rey and the other founders of Endpoint Health asked. 

Diego Rey is a co-founder and Chief Scientific Office of Endpoint Health, which is flipping the traditional drug development model on its head with a precision-medicine approach. In the past, biopharma companies would start with a molecule and then see where it can be used. Endpoint thinks differently. They are using deep patient insight from the patient’s biology, molecules, digital patient data and the latest in AI technology to create precision-first therapies. Pretty cool and unique approach especially for those who have traditionally been overlooked by generic drugs. 

We’re excited to have Diego on to talk more about their approach, the future of precision medicine, and his inaugural work with Y Combinator’s life sciences startups. 

About Diego
Diego Rey, PhD, is a co-founder, board member, and Chief Scientific Officer of Endpoint Health, a Precision-First™ biopharma company where he employs his background in building multidisciplinary technical teams to create and develop the core technologies that enable Endpoint Health to deliver therapeutics and diagnostics to improve patient care.

Diego holds a PhD in Biomedical Engineering from Cornell University with minors in Biophysics and Applied Engineering Physics and a BS in Electrical Engineering from the University of California at Santa Barbara. Prior to Endpoint Health, during his PhD Diego co-founded GeneWEAVE Biosciences that was acquired by Roche where he was Head of Research for the Roche GeneWEAVE Division. After Roche Diego joined Y Combinator as YC’s first life sciences Visiting Partner. 

https://www.linkedin.com/in/diegorey/ 

About Endpoint
Endpoint Health is a precision-first™ therapeutics company that building a new kind of biopharma. By rewriting the molecule-first drug development model, Endpoint aims to deliver precision therapies that have the potential to improve outcomes for patients with immune-driven illnesses. Their vision is a world in which all patients get the best treatment possible for their unique biology and disease.

https://endpointhealth.com/ 

https://endpointhealth.com/pipeline/ 

Qualio Website

Previous episodes: https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show: https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez

Qualio website:
https://www.qualio.com/

Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez